/Investor DB

Sphera Funds Management — Full Portfolio

3 tracked investments · listed companies and verified rows first

Passage Biopassagebio.comin𝕏NASDAQ: PASGSep 2019 · $110M

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersLilly Asia VenturesNew Leaf Venture PartnersOrbiMed+2 more

Field Trip Healthfieldtriphealth.comin𝕏Mar 2021

Field Trip Health provides ketamine-assisted therapy for treatment-resistant depression and anxiety, offering rapid symptom relief through clinically monitored ketamine administration combined with psychotherapy.

Digital HealthHealthtechMedical DevicesMental Health

Co-investorsBT Growth CapitalFrontera Technology VenturesEarl Grey CapitalJennison AssociatesPura Vida InvestmentsSoleus Capital

OncorusinAug 2019 · $79.5M

Cambridge, US

Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in

BoardBriggs Morrison(Director)inMitchell Finer(Executive Officer, Director)

Co-investorsAstellas Venture Management LLCCowen Healthcare InvestmentsDeerfield Management CompanyIMM InvestmentK2 HealthVenturesMPM BioImpact

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.